The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status.
Lung Cancer 73(2):203-10 (2011) PMID 21211862
To assess the risk/benefit profiles of EGFR TKIs monotherapy using erlotinib or gefitinib in comparison with single-agent chemotherapy using third-generation cytotoxics (gemcitabine, vinorelbine, taxanes) as the first-line treatment for chemonaÏve patients with advanced non-small cell lung cancer (ANSCLC) and poor performance status (PS).
Copyright © 2011 Elsevier Ltd. All rights reserved.
DOI: 10.1016/j.lungcan.2010.12.006
Version: za2963e q8zaf q8zbc q8zce q8zd2 q8ze4 q8zfa q8zg8